Dupixent (dupilumab) stands out as a fully human monoclonal antibody that has gained recognition for its therapeutic effects in multiple inflammatory conditions that involve the immune system. Dupixent received initial US FDA approval to treat atopic dermatitis along with asthma and chronic rhinosinusitis with nasal polyposis before expanding its investigation to chronic spontaneous urticaria (CSU). […]